<?xml version="1.0" encoding="UTF-8"?>
<p id="p0215">Similar to the SARS-CoV outbreak, therapeutic options such as ribavirin, interferons, and corticosteroids shown tiny to no clinical usefulness, notwithstanding efficacy exhibition in nonhuman primates 
 <xref rid="b0380" ref-type="bibr">[76]</xref>. The ongoing multicenter, randomized controlled trial, the MIRACLE (MERS-CoV Infection treated with A Combination of LPV/r and intErferon-β1b) trial targeting the result of 3 months fatality expected to come with conclusive investigations on the effectiveness of blend therapy of LPV/r and recombinant IF-β1b 
 <xref rid="b0385" ref-type="bibr">[77]</xref>.
</p>
